{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:27Z","timestamp":1790739027608,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070187"],"award-info":[{"award-number":["82070187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370213"],"award-info":[{"award-number":["82370213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070187,82370213"],"award-info":[{"award-number":["82070187,82370213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.108088","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:04:20Z","timestamp":1756191860000},"page":"108088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"157","author":[{"given":"Qiannan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2025.108088_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.leukres.2025.108088_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2016.251","article-title":"Inhibition of FLT3 in AML: a focus on sorafenib","volume":"52","author":"Antar","year":"2017","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.leukres.2025.108088_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428194.2013.800198","article-title":"FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations","volume":"55","author":"Kayser","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"9","key":"10.1016\/j.leukres.2025.108088_bib5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108088_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00050-x","article-title":"Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens","volume":"11","author":"Casta\u00f1o-Bonilla","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.leukres.2025.108088_bib9","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/1878-0261.12961","article-title":"FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation","volume":"15","author":"Engen","year":"2021","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108088_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-020-0318-1","article-title":"Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia","volume":"10","author":"Abou Dalle","year":"2020","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.leukres.2025.108088_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 european LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2025.108088_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.108088_bib13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.leukres.2025.108088_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jnci\/djm328","article-title":"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia","volume":"100","author":"Zhang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"25","key":"10.1016\/j.leukres.2025.108088_bib15","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2025.108088_bib16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2025.108088_bib17","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108088_bib18","unstructured":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)] 9 44 Zhonghua Xue Ye Xue Za Zhi, Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL)20237057122023."},{"issue":"4","key":"10.1016\/j.leukres.2025.108088_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.108088_bib20","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","article-title":"Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial","volume":"35","author":"R\u00f6llig","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2025.108088_bib21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.108088_bib22","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/leu.2014.54","article-title":"Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2025.108088_bib23","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT acute leukemia working party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.leukres.2025.108088_bib24","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2025.108088_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174315","article-title":"Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure","volume":"14","author":"Capelli","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.leukres.2025.108088_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.leukres.2025.108088_bib27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/leu.2010.122","article-title":"Identification of a secondary FLT3\/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib","volume":"24","author":"von Bubnoff","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2025.108088_bib28","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2025.108088_bib29","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","article-title":"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia","volume":"19","author":"Baker","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.leukres.2025.108088_bib30","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54738-2","article-title":"Cdc7 kinase stimulates aurora b kinase in M-phase","volume":"9","author":"Ito","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2019-122620","article-title":"Emerging mutations at relapse in patients with FLT3-Mutated Relapsed\/Refractory acute myeloid leukemia who received gilteritinib therapy in the phase 3 admiral trial","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108088_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s42003-021-02215-w","article-title":"Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia","volume":"4","author":"Garitano-Trojaola","year":"2021","journal-title":"Commun. Biol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625005788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625005788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:04:48Z","timestamp":1772823888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625005788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S0145212625005788"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108088","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108088"}}